BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 22287968)

  • 1. Towards curative therapy in burkitt lymphoma: the role of early african studies in demonstrating the value of combination therapy and CNS prophylaxis.
    Magrath I
    Adv Hematol; 2012; 2012():130680. PubMed ID: 22287968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Excessive spinal cord toxicity from intensive central nervous system-directed therapies.
    Watterson J; Toogood I; Nieder M; Morse M; Frierdich S; Lee Y; Moertel CL; Priest JR
    Cancer; 1994 Dec; 74(11):3034-41. PubMed ID: 7954266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab.
    Zhu KY; Song KW; Connors JM; Leitch H; Barnett MJ; Ramadan K; Slack GW; Abou Mourad Y; Forrest DL; Hogge DE; Nantel SH; Narayanan S; Nevill TJ; Power MM; Sanford DS; Sutherland HJ; Tucker T; Toze CL; Sehn LH; Broady R; Gerrie AS
    Br J Haematol; 2018 Jun; 181(6):782-790. PubMed ID: 29741758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Burkitt's lymphoma: the African experience.
    Olweny CL; Nkrumah FK
    IARC Sci Publ; 1985; (60):375-82. PubMed ID: 4065949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five decades of low intensity and low survival: adapting intensified regimens to cure pediatric Burkitt lymphoma in Africa.
    Ozuah NW; Lubega J; Allen CE; El-Mallawany NK
    Blood Adv; 2020 Aug; 4(16):4007-4019. PubMed ID: 32841337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of treatment with CMA, a low intermediate regimen, in endemic Burkitt lymphomas in sub-Saharian Africa: experience of Côte d'Ivoire.
    Koffi GK; Tolo A; Nanho DC; N'dathz E; Kouassi MY; N'Diaye FD; Kouakou B; Meité N; Ayemou R; Sekongo M; Kouehion P; Meité M; Tea ND; Sangaré A; Sanogo I
    Int J Hematol; 2010 Jun; 91(5):838-43. PubMed ID: 20480270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial.
    Chamuleau MED; Stenner F; Chitu DA; Novak U; Minnema MC; Geerts P; Stevens WBC; Zenz T; van Imhoff GW; Wu KL; Demandt AMP; Kersten MJ; Terpstra WE; Tick LW; Deeren D; Van Den Neste E; Gregor M; Veelken H; Böhmer LH; Caspar CB; Mutsaers P; Refos JM; Sewsaran R; Fu L; Seefat RL; Uyl-de Groot CA; Dirnhofer S; Van Den Brand M; de Jong D; Nijland M; Lugtenburg P
    Lancet Haematol; 2023 Dec; 10(12):e966-e975. PubMed ID: 37922925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination chemotherapy in abdominal Burkitt's lymphoma.
    Nkrumah FK; Perkins IV; Biggar RJ
    Cancer; 1977 Oct; 40(4):1410-6. PubMed ID: 907960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Burkitt's Lymphoma and B-Cell Lymphoma Unclassifiable With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt's Lymphoma in Patients With HIV: Outcomes in a South African Public Hospital.
    Sissolak G; Seftel M; Uldrick TS; Esterhuizen TM; Mohamed N; Kotze D
    J Glob Oncol; 2017 Jun; 3(3):218-226. PubMed ID: 28717763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 5-drug regimen maximizing the dose of cyclophosphamide is effective therapy for adult Burkitt or Burkitt-like lymphomas.
    Kujawski LA; Longo WL; Williams EC; Turman NJ; Brandt N; Mosher DF; Eickhoff JC; Kahl BS
    Cancer Invest; 2007 Mar; 25(2):87-93. PubMed ID: 17453819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Teniposide plus cytarabine as intensification therapy and in continuation therapy for advanced nonlymphoblastic lymphomas of childhood.
    Maluf PT; Odone Filho V; Cristofani LM; Britto JL; Almeida MT; Pontes E; Maksoud JG; Manissadjian A
    J Clin Oncol; 1994 Sep; 12(9):1963-8. PubMed ID: 8083717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of central nervous system (CNS) prophylaxis in preventing DLBCL patients from CNS relapse: A network meta-analysis.
    Lin Z; Chen X; Liu L; Zeng H; Li Z; Xu B
    Crit Rev Oncol Hematol; 2022 Aug; 176():103756. PubMed ID: 35809794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM group.
    Reiter A; Schrappe M; Ludwig WD; Lampert F; Harbott J; Henze G; Niemeyer CM; Gadner H; Müller-Weihrich S; Ritter J
    Blood; 1992 Nov; 80(10):2471-8. PubMed ID: 1421370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensive, very short-term chemotherapy for advanced Burkitt's lymphoma in children.
    Spreafico F; Massimino M; Luksch R; Casanova M; Cefalo GS; Collini P; Ferrari A; Polastri D; Terenziani M; Gasparini M; Fossati-Bellani F
    J Clin Oncol; 2002 Jun; 20(12):2783-8. PubMed ID: 12065554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved outcome in adult B-cell acute lymphoblastic leukemia.
    Hoelzer D; Ludwig WD; Thiel E; Gassmann W; Löffler H; Fonatsch C; Rieder H; Heil G; Heinze B; Arnold R; Hossfeld D; Büchner T; Koch P; Freund M; Hiddemann W; Maschmeyer G; Heyll A; Aul C; Faak T; Kuse R; Ittel TH; Gramatzki M; Diedrich H; Kolbe K; Fuhr HG; Fischer K; Schadeck-Gressel C; Weiss A; Strohscheer I; Metzner B; Fabry U; Gökbuget N; Völkers B; Messerer D; Uberla K
    Blood; 1996 Jan; 87(2):495-508. PubMed ID: 8555471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potentiating role of previously administered agents in the combination chemotherapy of breast cancer.
    Rosner D; Snyderman M; Nemoto T
    Oncology; 1979; 36(4):160-3. PubMed ID: 471428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Burkitt lymphoma in children and adults: Lessons from Africa.
    Magrath IT
    Curr Hematol Malig Rep; 2006 Dec; 1(4):230-40. PubMed ID: 20425318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.